Innovative Governance Models for Emerging Technologies

Innovative Governance Models for Emerging Technologies

Edited by Gary E. Marchant, Kenneth W. Abbott and Braden Allenby

Emerging technologies create challenges for traditional regulatory approaches. The contributors to this book – leading scholars in law, innovation, and technology – address the need for new governance methods and models.

Chapter 10: Innovative governance schemes for molecular diagnostics

Rachel A. Lindor and Gary E. Marchant

Subjects: innovation and technology, innovation policy, technology and ict, law - academic, environmental law, regulation and governance


Molecular diagnostics are expected to shepherd in a new paradigm in health care delivery known alternatively as personalized, individualized or precision medicine. The key distinction of this new approach is that health care decisions will be based on a patient’s individual molecular profile rather than on population or group characteristics or averages. Thus, for example, the selection and dose of a drug will be based on the particular set of variants present in the patient’s genome that affect drug metabolism. Diseases will be detected much earlier based on the presence or concentration of a protein biomarker in the patient’s blood, rather than waiting for the disease to manifest in clinical symptoms. The prognosis and best treatment option for a cancer patient will be determined by the changes in gene expression patterns in the patient’s tumor. These new molecular-based strategies for predicting, diagnosing, and treating disease are all dependent on sophisticated new molecular diagnostic tests. These molecular diagnostic tests will be the quarterbacks of the new personalized medicine paradigm. Just as a quarterback in football surveys the situation on the field, selects the appropriate play, and then sets that play in motion, molecular diagnostics will play a central role in assessing a patient’s health status and risks, selecting an appropriate intervention strategy, and then targeting the treatment based on the patient’s molecular profile.

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information